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The Bayesian expected power (BEP) has become increasingly popular in sample size
determination and assessment of the probability of success (POS) for a future trial. The
BEP takes into consideration the uncertainty around the parameters assumed by a power
analysis and is thus more robust compared to the traditional power that assumes a single set of
parameters. Current methods for assessing BEP are often based in a parametric framework by
imposing a model on the pilot data to derive and sample from the posterior distributions of the
parameters. Implementation of the model-based approaches can be analytically challenging
and computationally costly especially for multivariate data sets; it also runs the risk of
generating misleading BEP if the model is mis-specified. We propose an approach based on
the Bayesian bootstrap technique (BBS) to simulate future trials in the presence of individual-
level pilot data, based on which the empirical BEP can be calculated. The BBS approach is
model-free with no assumptions about the distribution of the prior data and circumvents the
analytical and computational complexity associated with obtaining the posterior distribution
of the parameters. Information from multiple pilot studies is also straightforward to combine.
We also propose the double bootstrap (BS2), a frequentist counterpart to the BBS, that shares
similar properties and achieves the same goal as the BBS for BEP assessment. Simulation
studies and case studies are presented to demonstrate the implementation of the BBS and
BS2 techniques and to compare the BEP results with model-based approaches.
KEY WORDS: double bootstrap; trial simulation; probability of success; robust decision
making; weighted average power; assurance
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1 Introduction
The probability of success (POS) of a clinical trial is affected by many factors such as
patient recruitment, ethical considerations, local regulations, resources, study designs and
execution, among others. The part where statisticians get involved the most is the study
design during the trial planning stage, including the sample size determination and power
calculation. Power is defined as the probability of rejecting the null hypothesis H0 if the
alternative hypothesis H1 is true in a future trial. The probabilistic nature of power makes a
natural choice as a metric for measuring how the statistical design aspect of the study affects
the POS of the trial. On the other hand, the classical power is a conditional probability
given a specific effect size ∆ = µ/σ, the value of which is an unknown quantity and is often
the parameter of primary interest to estimate in the planned trial. As such, the power is
sensitive to the assumed effect size and not a robust measurement of POS.
A more robust measurement for POS compared to the classical power is the Bayesian
expected power (BEP) or the weighted average power (WAP), which is the expected power
over the distribution of the effect size ∆ given existing data. In other words, the BEP is a
“marginal” measure of the POS given what’s known, integrating out the unknown ∆. The
BEP has been “re-invented” several times under different names in various contexts. Brown
et al. (1987) suggested using Bayesian methods to obtain a posterior distribution representing
the state of knowledge of the parameters of interest, and to predict the outcome of a specified
comparative trial. The approach was implemented and demonstrated in several examples in
Spiegelhalter et al. (2004). O’Hagan and Stevens (2001) and O’Hagan et al. (2005) used
the term “assurance” and Chuang-Stein (2006) used “average success probability” to describe
the BEP. In all thedr cases, only the uncertainty around µ concerned by the hypothesis
in the future trial is considered and the uncertainty around the variance σ, which is an
equally important parameter in power calculation, is not taken into consideration. Liu (2010)
extended the BEP by accounting for the uncertainty around both µ and σ (or the effect size
∆), and also added two more versions of the BEP to by removing the “type I error” component
from the regular BEP metric. Some recent reviews, discussion, and applications of the BEP
in early and late phased clinical trials, and in meta-analysis are given in Kirby et al. (2012);
Carroll (2013); Ibrahim et al. (2015); Du and Wang (2016); Zierhut et al. (2016). The
BEP has been routinely calculated alongside the traditional power in some pharmaceutical
companies; and it is also implemented in several sample size and power calculation software
(Labes et al., 2016; EAST-CYTEL, 2016).
The current approaches to assessing the BEP often start with constructing the joint
posterior distributions of µ and σ given a prior and the likelihood of the parameters given
the pilot/exisiting data. In many cases, the posterior distributions of µ and σ may not
have closed-form expressions, or even they do, iterative approaches, such as the MCMC
algorithms and other sampling techniques, might still be necessary to draw the parameters
from the posterior distributions. In the case when there are co-primary hypotheses, µ is multi-
dimensional, analytically and computational it becomes even harder. In summary, the model-
based approaches can be analytically challenging and computationally costly especially for
multivariate data. On top of all these, there is always the risk of misspecifying the likelihood
of the parameters with the pilot data, leading to misleading BEP values subsequently.
We propose an approach based on the Bayesian bootstrap technique (Rubin, 1981) ,
referred to as the BBS approach, to assess the BEP when individual-level pilot data y are
available. The Bayesian bootstrap is a Bayesian version of the bootstrap technique (Efron,
1979). Rubin (1981) proved that the Bayesian bootstrap is operationally and inferentially
similar to the frequentist bootstrap. In the BBS approach, we repeatedly simulate the future
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trial data given y via the Bayesian bootstrap technique without imposing any distributional
assumptions on y, and test H0 according to the planned analysis in each set of the simulated
trials; and the overall rejection rate of H0 over the repetitions leads to a Monte Carlo (MC)
estimate of the BEP. The uncertainty around the underlying true distribution of the pilot
data is accounted for by placing a Dirichlet prior on the probability of each individual. The
BBS approach is straightforward to implement with minimal analytical work except for the
planned analysis on the simulated future data. Computationally, only a few lines of codes are
needed to implement the sampling and trial simulation steps, and the whole BBS procedure
can be easily parallelized for fast computation. When there are multiple relevant pilot data
sets, it is straightforward to combine the pilot data together via the BBS approach.
Directly applying the regular bootstrap to the pilot data to simulate future data is
inappropriate for the purpose of BEP assessment since it will not propagate the uncertainty
around the distribution of the pilot data. As a matter of fact, the overall rejection rate based
on the future data simulated this way is a MC estimate of the classical power assuming the
estimated effect size from the pilot data is the true effect size. This motivates us to come up
with the “double bootstrap” technique (BS2), a frequentist counterpart to the BBS, that will
propagate the uncertainty around the distribution of the pilot data and achieves the same
goal as the BBS for BEP assessment. Procedurally, the BS2 first bootstraps the pilot data,
and then samples the bootstrapped pilot data to generate repetitions for the future trials
based on which a MC estimate of the BEP is obtained. Similar to the BBS, only a few lines
of codes are needed to implement the BS2, and it is easy to parallelize computationally.
The rest of the paper is organized as follows. Section 2 introduces the BBS and BS2
approaches for assessing the BEP. Section 3 compares the BBS and BS2 approaches with
the parametric approaches in the BEP assessment in two simulation studies. Section 4
implements the BBS and BS2 approaches to assess BEP for an equivalence study and for a
HIV survival study. Section 5 concludes the discussion with some final remarks. The R codes
for the numerical examples in Section 4 are provided in the online supplementary materials
to this paper and are also available for download at TBD.
2 Methods
2.1 assessment of BEP
By definition, the BEP is the probability of rejecting H0 in a future trial given existing
data y. Denote the classical power by β(θ) = Pr(rejecting H0|θ, n˜), where θ refers to the
parameters involved in the power calculation and n˜ is the given sample size of the future
trial, then
BEP = E[β(θ)|y] = ∫ β(θ)p(θ|y)dθ. (1)
To calculate the BEP, we may first draw θ from its posterior distribution p(θ|y), and then
plug in the drawn θ in the power function β(θ) to obtain a classical power value given the
drawn θ. Repeating the two steps many times, say m, will lead to the posterior distribution
of the power β given y, the average
∑m
j=1 β(θ
(j)) of the posterior samples is an MC estimate
for BEP for the future trial for a given n˜. Besides the BEP, other statistics from the posterior
distribution of the power can also be reported, such as the mode and the percentiles.
If a closed-formed function β(θ) is not available, the MC method can be applied to
numerically approximate the power by simulating the future trial data y˜ on which H0 will
be tested. Denote the event of rejecting H0 in the future trial by I(R(y˜)), where R is the
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rejection rule, a function of y˜, and I(R(y˜)) = 1 if H0 is rejected in y˜ and 0 otherwise, then
BEP = E [I(R(y˜))|y] = E [E[I(R(y˜))|θ,y]|y]
=
∫ ∫
I(R(y˜))p(y˜|y,θ)p(θ|y)dy˜dθ
=
∫ (∫
I(R(y˜))p(y˜|θ)dy˜) p(θ|y)dθ. (2)
Eqn (2) suggests that we can first draw θ from the posterior distribution p(θ|y) given pilot
data y, and simulate the future data y˜ of size n˜ given the drawn θ, then perform the planned
statistical analysis and hypothesis testing on the simulated data y˜, and record 1 if rejected
and 0 if not. Repeating the process many times, say m, and the rejection rate over the m
repetations is an MC estimate of the BEP. We refer to this MC approach for assessing the
BEP as the future trial simulation (FTS) approach.
Regardless of whether the model-based approach is employed when closed-form β(θ)
is available or the FTS approach is applied when it is not, the current approaches for the
BEP assessment are mainly model-based by imposing distributional or model assumptions
on the pilot data y to obtain the posterior distribution p(θ|y), followed by the posterior
sampling step. If y˜ and θ are multidimensional, the sampling of θ and simulation of y˜ can
be computationally costly, not to be mention the risk of mis-specification of the parametric
model, leading to misleading BEP subsequently. Alternative techniques that avoid making
strong parametric assumptions about data y and at the same time are computationally less
complicated are desired.
We propose a FTS technique, referred to as the BBS approach, motivated by the Bayesian
bootstrap to evaluate the BEP numerically. The BBS assesses the BEP without imposing
a model on the pilot data or sampling from complicated posterior distributions via MCMC
approaches. Instead, the BBS approach obtains the posterior distributions of the population
distribution underlying y given y, from which the future data will be simulated. We will
also present the frequentist version of the BBS approach – the “double bootstrap” technique
(BS2), and discuss why the regular bootstrap will only lead to a MC estimation of the classical
power instead of yielding the BEP.
2.2 construction of a posterior distribution of the population distri-
bution via Bayesian bootstrap
Define a finite population of sizeN withK (K <∞) distinct values over p attributes. Let
pik denote the probability that value dk occurs for k = 1, . . . , K. The Bayesian bootstrap can
be used to obtain a posterior distribution of the population distribution f of the K distinct
values given a data set y of size n. Denote by pi = (pi1, . . . , piK) the probabilities associated
with the K distinct values (
∑
k pik = 1). Since pi fully characterizes f , obtaining the posterior
distribution on f is equivalent to obtaining the posterior distribution of pi. A convenient
choice on the prior of pi is the Dirichlet distribution D(pi|α1, . . . , αK) ∝
∏K
k=1 pi
αk−1
k , with
hyper-parameters α = (α1, . . . , αK) > 0. Since Dirichlet priors are conjugate priors for the
multinomial likelihood, the posterior distribution of pi given data y (of size n) also follows
a Dirichlet distribution D(pi1, . . . , piK |n) ∝
∏K
k=1 pi
nk+αk−1
k , where n = (n1, . . . , nK), nk is the
number of observations in the sample that take the value dk, and
∑
k nk = n.
It is highly likely that not every distinct dk from the population will occur in the sample;
and nk’s associated with these “non-appearing” cases will be 0. Denote by L the number of
distinct cases in the sample (L ≤ K), the posterior distribution of the subset of pi that is as-
sociated with the sample cases is D(pi1, . . . , piL|n) ∝
∏L
k=1 pi
nk+αk−1
k . In practical application,
we can always set L = n due to two reasons: it does not affect the posterior distribution
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of pi associated with the distinct values given the aggregation property of the Dirichlet dis-
tribution; and every individual in the sample can be distinct from each other when there
are continuous variables among the p attributes or p is large. With L = n, nk = 1 for
k = 1, . . . , n, and The posterior distribution of pi can be simplified to
p(pi1, . . . , pin|y) =
∏n
i=1 pi
(αk+1)−1
k
B(α1 + 1, . . . , αn + 1)
= D(α1 + 1, . . . , αn + 1). (3)
In terms of the choice for the hyper-parameters αk, proper priors should have αk > 0 ∀ k =
1, . . . , n. If there are minimal information about pi prior to the pilot data y, setting αk
at small positive numbers (eg, 0.1, 0.5, 1, etc) leads to weakly informative priors for pi.
An improper non-informative but convenient choice is αk = 0 ∀ k = 1, . . . , n, which still
generates a proper posterior distribution for pi,
p(pi1, . . . , pin|y) = (Γ(n))−1 = D(1, . . . , 1). (4)
2.3 BEP assessment with Bayesian bootstrap
The Bayesian bootstrap is employed in the BEP assessment to simulate data y˜ for the
future trial, the posterior predictive distribution of which, given pilot data y, is
p(y˜|y) = ∫ p(y˜|y,pi)p(pi|y)dpi = ∫ p(y˜|pi)p(pi|y)dpi = ∫M(n˜,pi)p(pi|y)dpi, (5)
where p(pi|y) is given in Eqn (3) (Eqn (4) if αk = 0). Plugging in p(y˜|y) from Eqn (5) in
Eqn (2), we have
BEP =
∫∫
I(R(y˜))M(n˜,pi)p(pi|y)dpidy˜ (6)
Eqn (6) suggests that BEP can be calculated via the steps given in Table 1, which produces
a single metric of BEP rather than the posterior distribution of power. If it is desired to
have the posterior distribution of power, an inner loop will need to be built into the BBS
procedure, as given in Table 2. When the number of iterations of the inner loop t = 1, Table
2 reduces to Table 1.
DO j = 1, . . . ,m
1) draw pi(j) from the Dirichlet distribution in Eqn (3);
2) draw y˜(j) from M(n˜,pi(j));
3) test H0 in simulated trial y˜(j) and record I(R(y˜(j))) (1 if H0 is rejected; 0 otherwise);
END DO
OUTPUT: calculate BEP = m−1
∑m
j=1 I(R(y˜
(j))).
Table 1: BEP assessment via the BBS
2.4 the double boostrap
The BBS procedures in Tables 1 and 2 for assessing the BEP are based in the framework
of the Bayesian bootstrap. The frequentist counterpart to the BBS approach is the “double
bootstrap” (BS2) given in Table 3. The outer-loop bootstrap captures the uncertainty around
the population distribution (or the population parameters), corresponding to the sampling of
pi from its posterior distribution in the BBS procedure. The inner-loop bootstrap propagates
5
DO j = 1, . . . ,m
1) draw pi(j) from the Dirichlet distribution in Eqn (3);
2) given the drawn pi(j)
DO l = 1, . . . , t
2.1) draw y˜(l,j) from M(n˜,pi(j));
2.2) test H0 in simulated trial y˜(l,j) and record I(R(y˜(l,j))) (1 if H0 is rejected; 0 o.w.);
END DO
3) calculate power β(pi(j)) = t−1
∑t
l=1 I(R(y˜
(l,j))).
END DO
OUTPUT: m samples from the posterior distribution of power: (β(pi(1)), . . . , β(pi(m)))
and BEP = m−1
∑m
j=1(β(pi
(j)).
Table 2: Generation of the posterior distribution of power via the BBS
the sampling variability and error for the future trial, serving the same purposes of drawing
a sample data set given pi in the BBS procedure. The BS2 technique outputs samples from
a distribution of power given pilot data y, the average of which gives the WAP, taking into
account the uncertainty of the sample data. When m→∞, the BS2 technique is equivalent
to the BBS approach when the hyper-parameters αk = 0 ∀ k = 1, . . . , n. Strictly speaking,
the BS2 is not Bayesian conceptually, and the distribution of the power generated from the
procedure is thus not a posterior distribution though it is a conditional distribution given the
pilot data y, and the mean of which is asymptotically equivalent to the BEP. Setting t = 1
for the inner loop in Table 3 yields a single WAP estimate without a distribution of power
(similar to Table 2 being reduced to Table 1 in the BBS).
DO j = 1, . . . ,m
1) bootstrap a sample S(j) of size n from y with replacement;
DO l = 1, . . . , t
2.1) bootstrap y˜(l,j) of size n˜ from S(j) with replacement;
2.2) test H0 in simulated trial y˜(l,j) and record I(R(y˜(l,j))) (1 if H0 is rejected; 0 o.w.);
END DO
3) calculate power β(pi(j)) = t−1
∑t
l=1 I(R(y˜
(l,j))).
END DO
OUTPUT: m samples from the conditional distribution of power given y:
(β(pi(1)), . . . , β(pi(m))), and EP = m−1
∑m
j=1(β(pi
(j)).
Table 3: Generation of the conditional distribution of power given pilot data via the BS2
If we directly simulate the future data y˜ via the regular bootstrap, we end up having
a procedure (Table 4) that leads to a MC estimate of the classical power assuming what’s
observed in the pilot data is the truth. It is obvious that this procedure does not take account
DO j = 1, . . . ,m
1) bootstrap y˜(j) of size n˜ from y with replacement;
2) test H0 in y˜(j) and record I(R(y˜(j))) (1 if H0 is rejected; 0 o.w.);
END DO
OUTPUT: power = m−1
∑m
j=1 I(R(y˜
(j))).
Table 4: Monte Carlo power via FTS given pilot data
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the uncertainty around the unknown population distribution underlying y, thus implicitly
assumes the observed pilot data is the whole population and the estimated effect size from
y is the true effect size of the population.
3 Simulation Studies
We run two simulation studies to implement the BBS and BS2 procedures in Tables 2
and 3 to assess the BEP, and compared the results to the model-based BEP with an assumed
model on the pilot data. We also computed the classical power we compared the MC power
via the bootstrap procedure in Table 4 to the model-based power assuming the observed
results from the pilot study is the truth. The type I error rates in the hypothesis testing in
future trials were 5% in both simulation studies.
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Figure 1: Histogram of the differences between two metrics (model-based vs BBS BEP; BBS
vs BS2 BEP; model-based vs bootstrap power; and power vs BEP over 2500 repetitions in
Simulation 1 (gray bars: A < B in the A vs B comparison, pink bars: power A > B)
In the first simulation study, 2500 repetitions were run. In each repetition, a pilot of
study of size n was simulated from N(µ = 0.15, σ = 1). We examined 3 cases of n: n =10,
30 and 100, respectively. The future trial under planning had n˜ = 500 and the hypotheses
were H0 : µ = 0 vs H1 : µ 6= 0 . The power assuming the effect size from the pilot study
was true and the BEP were calculated analytically and via the bootstrap procedures. Figure
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1 depicts the distributions for the differences over the 2500 repetitions between the various
metrics, and the results are summarized as follows. First, the BEP calculated analytically
and via the BBS and BS2 was similar; the small discrepancy between the two decreased with
n (the first and second rows). Second, the power calculated via the bootstrap procedure
was similar to the model-based power; the small discrepancy between the two decreased
with the pilot study size n (the first row). Third, the BEP could be larger or smaller than
power, depending on the pilot data. The mean difference between the two increased with n
and the dispersion of the difference decreased (the fourth row). From the histograms and
the empirical CDFs (cumulative distribution functions) of the power and BEP presented in
the online supplementary materials, we observe that the CDFs of the power and the BEP
intersected when power and BEP around 0.5 regardless of n. As n increased, the distribution
of the power became less ”bi-polar” while that of the BEP became less uniform, and the two
distributions became more similar.
In the second simulation study, 1000 repetitions were run. In each repetition, a pilot of
study of size n was simulated from a bivariate lognormal distribution LN(µ = (3, 5)′,Σ =
(10.65
0.65
1 )). We examined 3 cases of n: 10, 30, and 50. The future study had n˜ = 80 and the
hypotheses were H0 : (µ1≤2.7)∪ (µ2≤4.5) vs.H1 : (µ1>2.7)∩ (µ2>4.5). Power assuming the
effect size from the pilot study was true was calculated both analytically and via the bootstrap
procedure, and the model-based BEP with a correctly specified model on the pilot data (a
lognormal distribution) and with a wrongly specified model (a normal distribution), and the
BEP via the BBS and BS2 procedures were calculated. Figure 2 depicts the distributions of
the differences over the 1000 repetitions between the metrics. The histograms of the metrics
(2 powers, and 4 BEPs) over the 1000 simulations and their empirical CDFs are available
in the online supplementary materials. The results on the comparisons between the model-
based (correctly specified) vs bootstrap power, between the model-based (correctly specified),
BBS, and BS2 BEP, and between the power and BEP are similar to those in Simulation 1.
In terms of the model-based BEP based on the correctly specified model vs the wrongly
specified model on the pilot data, Figure 2 (the first row) suggests the BEP based on the
wrong model was smaller than the correct BEP by 2.4% to 5.6% on average, with larger n
blunting the effect of the model mis-specification on the BEP assessment.
4 Cast Studies
We implemented the BBS and the BS2 procedures in two case studies. The future trial
in the first example is a 2-period crossover study with an equivalence hypothesis and the
pilot study is a 3-period crossover study. In the second example, the future trial is a two-arm
study comparing the survival time of AIDS patients on two different treatments via the joint
modelling of the survival data and the longitudinal data on CD4 counts; and the pilot study
is of the same design but is smaller in size. The type I error rates in both examples are 5%.
4.1 example 1: crossover study with equivalence hypothesis
A 2-period crossover study (sample size n˜ = 200) is under planning with the goal of de-
veloping a new formulation for a fixed-dose combination (FDC) drug for treating dislipidemia
that has similar pharmacokinetic (PK) profile as a reference formulation R. The H1 states
that the geometric mean ratios (GMRs) between the FDC and R are within the interval of
(0.80, 1.25) on 4 PK endpoints: 2 measures on the area under the PK curve (AUC) and 2
measures of the maximum concentration (Cmax) on two chemical entities. There exists a
small pilot 3-period crossover study (n = 36) with two candidate FDC formulations FDC1
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Figure 2: Histogram of the differences between two metrics (model-based BEP based wrong
vs correct models on the pilot data; model-based vs BBS BEP; BBS vs BS2 BEP; model-
based vs bootstrap power; and power vs BEP over 1000 repetitions in Simulation 2 (gray
bars: A < B in the A vs B comparison, pink bars: power A > B)
and FDC2, and the reference formulation R. The team aims to use the test formulation with
the higher POS in the planned trial based on the information collected in the pilot study.
When modelling a single normally distributed endpoint yi = (yi1, . . . , yip)T from a
crossover study with p repeated measures, the linear mixed-effects (lme) model yi = xiβ +
ziγi+ i is often used. The fixed-effects term β often includes an intercept, treatment effects,
and period effects. The random effects term γi ∼ N(0,G) and the error term i ∼ N(0, R)
together define the variance/covariance V(yi) = Σ = ziGzi + R; and Σ can be as simple
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as “compound symmetry” (CS) structure (constant marginal variance on the diagonal and
constant covariance on all the off-diagonals) or as complex as “unstructured” (UN) (fully
parameterized with p(p+ 1)/2 parameters).
In the model-based assessment of BEP, we first obtained the posterior distribution of the
treatment differences (on the log-scale) between T1 and R, and between T2 and R given the
pilot data (AUC and Cmax in BE studies are often analyzed on the log scale). The hypothesis
to be established in the future trial is a union of 4 BE hypotheses, one per primary endpoint.
Therefore, the power is the joint probability that the 95% CIs for the 4 GMRs fell within
the interval of (0.80, 1.25) simultaneously. To model the dependency structure among the 4
endpoints, we analyzed all 4 endpoints in one lme model with a fully parameterized covariance
matrix Σ12×12. The likelihood function of (β,Σ) was
L(β,Σ; y,x) =
∏n
i=1 (2pi|Σ|)−1/2 exp{(yi − x′iβ)′Σ−1(yi − x′iβ)}. (7)
We imposed the prior p(β,Σ)∝|Σ|−(ν0+p+1)/2 on Σ, which is an inverse Wishart distribution
with the a priori degrees of freedom ν0, scale matrix |Σ0| → 0, and p = 12. We tried
two different ν0 at 0 and p + 1, respectively, to examine the impact of different parametric
assumptions on the model-based BEP. ν0 = 0 corresponds to the (improper) Jeffreys prior.
When ν0 = p+ 1, the conditional posterior mean E(Σ|β,y) is the same as the MLE for Σ if
β is known. The joint posterior distribution of (β,Σ) was
p(β,Σ|y,x) ∝ |Σ|−(ν0+p+1+n)/2 exp{(yi − x′iβ)′Σ−1(yi − x′iβ)}. (8)
In the pilot study, 5 individuals out of 36 had missing values (missing at random) from at
least one periods. To draw (β,Σ) from their posterior distribution, we used the imputation-
posterior (IP) algorithm and the Gibbs sampler by imputing ymis given Σ and β (the impu-
tation step in Eqn (9)) and drawing Σ and β respectively from their full conditional posterior
distributions given yobs and the imputed ymis (the posterior step in Eqns (10) and (11)).
The technical details on the derivation of the equations are provided in the Appendix.
p(ymis|β,Ω,yobs) = N (xmisβ,MΩM ′) , (9)
p(Σ|β,ymis,yobs) = Inv-Wishart(
∑n
i=1 eie
′
i, ν0 + n)
=
|Σ|−(ν0+n+p+1)/2|∑ni=1 eie′i|n/2exp {−tr (∑ni=1 eie′iΣ−1) /2}
2(n×p/2)Γp(n/2)
, (10)
p(β|Ω,ymis,yobs) = N
(
(x′Ω−1x)−1x′Ω−1y, (x′Ω−1x)−1
)
. (11)
Mnp×np in Eqn (9) was a diagonal indicator matrix of missingness on each observation with
mjj = 1 if the jth response was missing and 0 otherwise for j = 1, . . . , np;
∑n
i=1 eie
′
i =∑n
i=1(yi−xiβ)(yi−xiβ)′ in Eqn (10) was the scale matrix of the inverse Wishart distribution
and 2ν0 +n−p−1 was the degree of freedom; y = (yobs,ymis) and Ω was the block diagonal
matrix with n blocks of Σ in Eqn (11). Upon the convergence of the IP algorithm, after the
burn-in and thinning periods, 1000 sets of posterior samples of (Σ,β) were kept, based on
which, 1000 power values were calculated analytically for the future trial via a multivariate t
distribution that incorporated the dependency structure among the 4 endpoints (refer to the
online supplementary materials for the R function on the power calculation). The average of
the 1000 power values yielded the model-based BEP.
The BEP assessment via the BBS and the BS2 techniques was much more straightforward
than the model-based approach. Not only they involved minimal analytical work, coding of
the procedures was also easy. After the steps in Table 2 and Table 3 (m = 1000 and t = 1),
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we tested the 4 equivalence hypotheses via a lme model by endpoint in each of the simulated
trials via the BBS and BS2 procedures. If the 95% Cls of the log treatment differences for
all 4 endpoints fell within (log(0.8), log(1.25)), the future trial was claimed a success. The
success rate out of the 1000 simulated trials was the BEP.
We also computed the classical power analytically and via the bootstrap approach (Table
4). In the model-based approach, the log-scaled treatment differences in the 4 endpoints and
the variance/covariance structure Σ12×12 were estimated from the pilot study by fitting a lme
model. We modelled Σ with two different structures to examine the sensitivity of the model-
based power to the assumed model: a UN Σ and a Kronecker product Σ = Σ1
⊗
Σ2 between
a UN Σ1 across the 4 endpoints and a CS Σ2 across the 3 periods on the same endpoint.
The estimated treatment differences and Σ were then fed into the multivariate t-based power
function to obtain the power. In the bootstrap approach, 1000 sets were generated and the
hypothesis testing in each simulated y˜ was the same as in the BBS and BS2 procedures. The
success rate out of the 1000 trials was the bootstrapped power.
Though the pilot study is a 3-period crossover study while the future study is 2-period,
the model-based power and BEP values calculated above were legitimate since the treatment
differences were adjusted for the period effects through the lme models fitted to the pilot
data (model-based) or to the future data (bootstrap-based); and it was not necessary to
produce the “exact” 2-period crossover data in the FTS approach. In other words, the design
inconsistency between the pilot and future trials was not a concern from the perspective of
the treatment comparison as along as the period effects were properly taken care of.
The results are presented in Table 5 and summarized as follows. First, the BEP values
via the BBS and BS2 procedures were similar. Second, the model-based BEP and power
values were notably sensitive to the underlying parametric assumptions. The assumptions on
the dependency structure Σ among the endpoints influenced the estimates on the treatment
differences in the pilot data, leading different power and BEP values under each assumption.
Specifically, for BEP, different priors on Σ led to a ∼25% difference; in the case of power, dif-
ferent structural assumptions on Σ led to a 25%∼35% difference. Third, the parametric and
bootstrapped POS estimates were different in most cases. Fourth, T1 had consistently higher
BEP than T2 though the absolute values varied by the assessment approach. The relative
POS of T1 and T2 measured by the classical power were slightly inconsistent depending on
the assessment approach. All taken together, we would recommend T1 for the future trial and
cite the BEP obtained via the BBS and BS2 procedures given their robustness (model-free
incorporation of the uncertainty around the parameters in the power calculation).
BEP (%) Power (%)
treatment model- model- BBS BS2 model- model- BS
based†1 based
†
2 based
‡
1 based
‡
2
T1 51.0 74.3 86.3 87.6 99.98 65.8 100.0
T2 42.6 68.0 79.4 81.6 99.39 78.6 99.3
† Prior f(Σ)∝|Σ|− p+12 in parametric1;∝|Σ|−(p+1) in parametric2 (p=12)
‡ A fully parameterized Σp×p (p=12) was assumed on the pilot data in parametric1, and
Σ=ΣUN⊗ΣCS was assumed in parametric2 (ΣUN was fully parameterized across 4 endpoints,
and ΣCS followed a CS structure across the 3 repeated measures per endpoint).
Table 5: POS assessment of each test formulation in the future BE study
11
4.2 example 2: joint modeling of survival time and longitudinal data
The pilot study is a randomized trial in 40 AIDS patients who had failed or were intol-
erant of zidovudine (AZT) therapy (simulated from a published data set in Goldman et al.
(1996)). The patients were allocated to two antiretroviral drug treatment groups (A and B)
in a 1:1 ratio. Both the time to death due to AIDS and the CD4 count at 4 times points (0,
2, 6 and 12 months) were collected in the pilot study. Each patient was followed up for a
minimum of 12 months and with an average of 15.6 months. Based on the results from the
pilot study, a larger study of size n˜ is under planning to compare the two treatments in a
more confirmatory manner and to test the hazard ratio of death between the two against 1.
The team is interested in the assessment of the POS of the future trial.
In the model-based assessment of the BEP, the Bayesian joint modelling of the survival
time (with right censoring) and the CD4 counts was applied. Specifically, the square root of
the CD4 count yij in subject i at time tj was modeled with a lme model after the square-
root transformation; and the Cox model was applied to analyze the survival time with the
conditional expected mean of yij as a covariate, plus the effect from the treatments (Eqn 12).
yij(t) = ηij + ij(t) = xij(t)β + zij(t)bi + ij,
hi(t) = h0(t) exp(γxi2 + ληij(t)), (12)
log(h0(t)) = γ0 +
∑L
l=1 γlBl(t,k),
xij(t) is the covariates for patient i at time tj that includes an intercept, the time when yij
was measured (xij1(t)), the dummy variables for treatment xi2, whether there was previous
AIDS diagnosis at the study entry (xi3), and whether the patient had AZT intolerance or
AZT failure (xi4); β contains the fixed effects associated with xij(t); the random effect
bi = (bi0, bi1)
′ ∼ N(0,G2×2) corresponds a random intercept and a random slope for xij1(t);
and error term ij ∼ N(0, σ2). λ in Eqn (12) quantifies the association between the CD4 count
up to time t and the hazard for death at t, and γ is the log hazard ratio for death between the
two treatments. The baseline hazard h0(t) was modelled with the penalized-splines approach,
where Bl(t,k) is the lth basis function of the splines at knots k = (k1, . . . , kL) (we set L = 8)
and γl’s are the spline coefficients. The R package JMbayes was employed to fit the joint
model in Eqn (12). After the convergence of the MCMC algorithm, 2000 posterior samples
on the model parameters, including bi, were obtained (after 1000 burn-in and 40 thinning),
from which the posterior probability of survival pi = Pr(ti ≤ T ) by some time T in subject
i was obtained for i = 1, . . . , 40. We examined two types of T : the last recorded time in the
pilot study, which was 20.87 and 20.27 months in Treatments A and B, respectively; and 24
months, which was an extrapolation of the pilot data in study duration. The model-based
power for testing H0 : HR = 1 is Φ
(√
n˜(1− p)γ2/2− Φ−1(1− α/2)
)
, where n˜(1− p) is the
expected number of events in the future trial, where p = n−1
∑n
i=1 pi, and α is the type-I
error rate. Power was calculated at each of the 2000 posterior samples of (p, γ), the average
of which gave the model-based BEP. The model-based power given the posterior means of γ
and p at two types of T was also calculated.
In the bootstrap-based approaches,m = 500 sets of future data were generated according
to the steps in Table 1 and Table 3 (t = 1). In each simulated trial, the joint model in Eqn
(12) was applied, and the 95% posterior interval on the HR was obtained. If the lower bound
of the interval was > 1 or the upper bound was < 1, then the future trial was claimed a
success; the success rate out of 500 was the BEP. The bootstrap-based power based on Table
3 was also calculated. Different from the model-based approach, extrapolation to a longer
study duration (T = 24) was not possible without further parametric assumptions. In other
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words, the BEP and power evaluated via the bootstrap-based approaches implicitly assumed
the study duration in the future trial was the same as that in the pilot study.
The results of POS at different n˜ are provided in Table 6. The model-based BEP and
the BEP via the BBS and BS2 procedures were similar in this example, so were between
the model-based power and the bootstrap power. In summary, the POS for the future trial
reached 80 ∼ 85% at n˜ = 400, which might be an acceptable level of POS. As expected, a
longer study duration (24 months) led to an increase in the POS (by 5% ∼ 10%) compared
to the same sized future trial with the same study duration as the pilot study. By contrast,
all the POS values assessed by the power were close to 100% at all n˜ and for both study
durations, thus not a differentiable nor a valuable metric in determining n˜ .
n˜ T was the same as pilot study T = 24 months
allocation BEP(%) Power (%) BEP(%) Power†(%)
ratio 1:1 model-based BBS BS2 model-based† BS model-based
200 73.4 75.0 73.6 99.6 90.4 83.0 >99.9
400 81.8 83.0 84.5 >99.9 99.2 88.3 100.0
600 85.5 87.0 86.5 100.0 99.8 90.5 100.0
† The model-based power was also calculated with the sample survival probability (57.5%) and the
posterior mean of log-HR from the Bayesian joint model in the pilot data; the results were similar.
Table 6: Empirical POS assessment for the future trial to compare two antiretroviral drugs
in hazard of death in HIV patients
5 Discussion
We developed the BBS procedure based on the Bayesian bootstrap to calculate the
BEP given individual-level pilot data. We also presented a non-Bayesian counterpart to the
BBS procedure, named the double bootstrap (BS2), that achieves the same goal as the BBS
for the BEP assessment. Neither procedures make assumptions about the distribution of
the pilot data and can handle multidimensional data sets without imposing a dependence
structure among the variables. The implementation of both procedures are straightforward:
only a few lines of codes are needed and the whole procedures can be easily parallelized for
fast computation. By contrast, the parametric approaches specify a likelihood function on
the pilot data set and priors for the model parameters, followed by posterior sampling of
the parameters involved in the analytical power calculation. The derivation of the posterior
distributions and the posterior sampling can be complicated and computational costly, not
to mention the possibility of model mis-specification on the pilot data.
In the case of existence of multiple sets of pilot data, the data sets can be easily combined
to simulate the future trial. The weight associated with each pilot study, in terms of their
contribution to the future data, by default would be the size of the pilot studies: the larger the
sample size of a pilot study, the more likely the subjects from that study will be bootstrapped.
If other weights are desired and specified (e.g., the design agreement between the pilot and
future trials, the quality of the pilot data), they can be conveniently incorporated using a
2-stage sampling procedure: first sampling the studies with probabilities proportional to the
corresponding weights and followed by the regular BBS and BS2 procedure within each study.
The bootstrap-based approaches require the pilot information to be available in the form
of individual-level data. When there exist only historical summary/aggregate statistics, the
bootstrap-based approaches are not directly applicable. Though future data can be simu-
lated from the aggregate statistics, it would require additional distributional assumptions,
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defeating the purposes of developing the nonparametric bootstrap methods in the first place.
In practice, the pilot study might not be perfectly matched up to simulate the future trial
such as the design discrepancy between the two. Some design differences may not have di-
rect impacts on the planned analysis on the future trial or can be adjusted for in the BEP
calculation, and thus will not be a concern (e.g., the first case study). If a discrepancy that
relates to the effect size in the power calculation is not easy to adjust for without making
further parametric assumptions (such as the second example where the study duration could
be different), the model-based approaches might be the only choice. However, if unreasonable
extrapolation has to made, the parametric approaches would not be appropriate either.
In summary, the BBS and BS2 approaches provide an alternative to the parametric
approaches to assess the BEP. The bootstrap-based procedures will appeal to non-Bayesian
practitioners given their analytical and computational simplicity and easiness in implemen-
tation. We provide the sample R functions on the BBS and BS2 procedures in the online
supplementary materials to facilitate their practical implementation.
Supplementary materials
The supplementary materials can be found at http://www3.nd.edu/~fliu2/BBS-supp.pdf
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Appendix A: Conditional posterior distributions of Σ and β in case study 1
This appendix presents the derivation of the posterior distribution of Σ and β in linear mixed
models. Denote the number of subjects by n and the number of measurements per subject by
p. The likelihood of Σ and β is L(Σ,β|y)∝∏ni=1{|Σ|−1/2exp (−12(yi − xiβ)TΣ−1(yi − xiβ))}.
Let the prior on β and Σ be p(β,Σ)= |Σ|−(ν0+p+1)/2. The full conditional posterior distribu-
tion of Σ given (β,y) is
p(Σ|β,y) ∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
∑n
i=1(yi − xiβ)tΣ−1(yi − xiβ)
)
∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
∑n
i=1 tr(eie
T
i Σ
−1)
)
∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
tr
(∑n
i=1 eie
T
i Σ
−1)) , where ei = yi − xiβ.
Thus p(Σ|β,y) = |Σ|
−(ν0+p+n+1)/2|∑ni=1 eieti|n/2exp (−tr (∑ni=1 eietiΣ−1) /2)
2(mn/2)Γn(m/2)
,
which is an inverse Wishart distribution W−1(
∑n
i=1 eie
t
i, n) with scale matrix
∑n
i=1 eie
t
i and
the degrees of freedom n. The full conditional distribution of β given (Σ,y) is
p(β|Σ,y) ∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
∑n
i=1(yi − xiβ)TΣ−1(yi − xiβ)
)
∝ |Σ|−(ν0+p+n+1)/2exp
(
−1
2
∑n
i=1
(
Σ−1/2(yi − xiβ)
)T (
Σ−1/2(yi − xiβ)
))
∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
(
βT (
∑n
i=1 x
T
i Σ
−1xi)β
−∑ni=1 yTi Σ−1xiβ − βT∑ni=1 xTi Σ−1yi +∑ni=1 yTi Σ−1yi))
∝ |Σ|−(ν0+p+n+1)/2exp (−1
2
(
βT (xTΩ−1x)β − yTΩ−1xβ − βTxTΩ−1y + yTΩ−1y))
∝ |Σ|−(ν0+p+n+1)/2
exp
(
−1
2
(
β − (xTΩ−1x)−1(xTΩ−1y))T ((xTΩ−1x)−1)−1 (β − (xTΩ−1x)−1(xTΩ−1y))) .
Thus p(β|Σ,y) = N ((xTΩ−1x)−1(xTΩ−1y), (xTΩ−1x)−1), where Ω is a block diagonal matrix
with n blocks of Σ on the diagonal, x = {xi}i=1,...,n, and y = {yi}i=1,...,n
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